Liège, Belgium 21 October 2015 – Mithra Pharmaceuticals SA/NV announced that it has signed an agreement with Chiltern for the Phase II dose-finding study of its Estetrol-base product candidate Donesta®, a hormonal replacement therapy for menopausal women. This study called E4Relief is expected to start H1 2016 and to be finished end 2016. This contract amounts to EUR 4,5 million.